Shows
dewadewi@Download The Biotech Primer One: The Science Driving Biopharma Explained: An Insider’s Guide to the Science Driving the Biopharma Industry for the Non-Scientist (The Biotech Primer For Non-Scientists Series) – Biotech PrimerDownload Ebook PDF The Biotech Primer One: The Science Driving Biopharma Explained: An Insider’s Guide to the Science Driving the Biopharma Industry for the Non-Scientist (The Biotech Primer For Non-Scientists Series)Full Read
Click Here To Download Book:
Link: https://khalledberdoa.blogspot.com/?book=B08W7JTW8M
Available versions: EPUB, PDF, MOBI, DOC, Kindle, Audiobook, etc.
Discover the Bestseller Everyone is Talking About:
Reading The Biotech Primer One: The Science Driving Biopharma Explained: An Insider’s Guide to the Science Driving the Biopharma Industry for the Non-Scientist (The...2025-07-2200 min
Flagship PodcastEnhancing Scientific Reasoning in Biopharma with Christopher Li, CEO & Co-Founder @ BioBoxIn this episode, Chris, co-founder of Bio Box, delves into the innovative solutions his company offers to the biopharma sector. Bio Box provides a knowledge and reasoning infrastructure for biopharma R&D, helping scientists scale up hypothesis generation and testing in early drug discovery. Chris explains how their platform integrates various biomedical data sources to enable quicker, data-driven decisions and improve collaboration across research teams. He also discusses the challenges and rewards of building a startup in the biotech industry, particularly in the Canadian context, and shares insights on the importance of productive science and reasoning in drug discovery...2025-07-2237 min
TD Cowen InsightsThe Current State of the Biopharma Development Industry w/ Brian WhitlockRecorded on 06/25/25In this episode, we will discuss the current state of the biopharma industry. Coming out of the pandemic, the biopharma research and development industry saw a wave of innovation and investment. However, as we move further beyond the pandemic, biopharma has begun to experience a multitude of headwinds, including the IRA, patent expirations, changes at the FDA, NIH funding cuts, and efforts to regulate drug pricing. This influx of pressure has forced the biopharma industry to rethink how it conducts its research and development programs.To help us discuss these topics and more...2025-07-0337 min
Pharmacy Tech Unfiltered3 Biopharma Jobs for Pharmacy Techs Without Degree: Career Switch Series Part 2Ever felt stuck in your pharmacy technician job—like you’ve outgrown the IV room, the retail chaos, or the endless night shifts?In this episode of Pharmacy Tech Unfiltered Career Switch Series, we’re talking about something most techs never hear about: careers in biopharma.I’ll share my personal story of how I went from feeling burned out in sterile compounding to finding real growth and balance in the biopharmaceutical industry—without a science degree.Whether you're exploring a pharmacy technician career change or just wondering what else your skills qualify you for, this episode will open doors.🔍 Yo...2025-06-1722 min
The Good Tech CompaniesAI-Powered Biopharma: Mahesh Recharla’s Blueprint for Smarter, Resilient Supply Chains
This story was originally published on HackerNoon at: https://hackernoon.com/ai-powered-biopharma-mahesh-recharlas-blueprint-for-smarter-resilient-supply-chains.
Mahesh Recharla proposes an AI-driven, cloud-based framework to transform biopharma logistics into a predictive, personalized, and compliant ecosystem.
Check more stories related to machine-learning at: https://hackernoon.com/c/machine-learning.
You can also check exclusive content about #ai-in-biopharma-logistics, #mahesh-recharla, #predictive-supply-chain, #digital-twin-healthcare, #supply-chain-optimization, #cloud-based-logistics, #gmp-compliance-ai, #good-company, and more.
This story was written by: @jonstojanjournalist. Learn more about this writer by checking @jonstojanjournalist's about page,
and for more stories, please visit hackernoon.com.
Mahesh Recharla introduces an AI-powered framework to optimize biopharma supply...2025-06-1706 min
NewsRamp Health & Wellness PodcastAccelerated Launch of FDA's AI Tool Elsa Raises Concerns and Excitement in Biopharma IndustryThe FDA has launched its AI tool, Elsa, ahead of schedule and under budget, leading to concerns about transparency and oversight. While some FDA staff viewed the rollout as rushed, regulatory experts are calling for public disclosure of Elsa's training and testing process. In the biopharma industry, Kamada Ltd. is increasing efforts to promote its CMV treatment CYTOGAM, while ABVC BioPharma's affiliate OncoX BioPharma Inc. has acquired the Lycogen® platform to develop targeted oncology indications. Meanwhile, United Health Products, Inc. is in the process of addressing FDA requests regarding its Investigational Device Exemption application for CelluSTAT Hemostatic Gauze.2025-06-0605 min
NewsRamp Industrial & Manufacturing PodcastMining and Biopharma Updates: Ramp Construction at McEwen Mining Inc. and Lycogen® Platform Acquisition by ABVC BioPharmaMcEwen Mining Inc. is constructing a ramp at its Stock Mine to enhance gold production, reduce costs, and improve operational efficiency. Meanwhile, ABVC BioPharma's affiliate OncoX BioPharma Inc. has acquired the Lycogen® platform, expected to generate revenue in oncology, dermatology, and nutraceutical sectors. ABVC's strategic product licensing model is successful, with a deal valued at up to $105 million, tapping into the growing oncology drug market and lycopene-based ingredients market.2025-06-0603 min
The Future of Commerce PodcastThe cold truth: Why biopharma needs integrated cold chain monitoring techFrom compromised vaccines to failed clinical trials, the stakes of biopharma cold chain failures are dangerously high. Each year, the industry loses $35 billion due to temperature excursions and environmental deviations in transit. But the cost to patient safety? Incalculable.In this episode, we examine the hidden weak points in cold chain logistics and why manual processes and siloed systems are no longer acceptable. Drawing from The cold truth: Why biopharma needs integrated cold chain monitoring tech, we uncover how IoT devices, smart packaging, and ERP-integrated platforms are transforming temperature-sensitive logistics—from warehouse to drone-based last-mile delivery.2025-06-0416 min
The Top LineElevAAte and the push for East Asian American leaders in biopharmaAlthough East Asians make up a significant share of entry-level roles in U.S. biopharma, few have risen to senior leadership positions. That disparity is what inspired the launch of ElevAAte—a new nonprofit founded this year to support and grow East Asian American leadership in the industry. In this week’s episode of "The Top Line," Fierce Pharma Deputy Editor Angus Liu speaks with two of ElevAAte’s co-founders: Architect Therapeutics CEO Angie You and Candid Therapeutics CEO Ken Song. The veteran biotech leaders discuss why a group like ElevAAte is needed and how East Asian Americ...2025-05-0235 min
Small Stocks, Big MoneyInterview with Connect Biopharma CEO Barry Quart | Transforming Acute Asthma & COPD CareConnect Biopharma Holdings Ltd. (Nasdaq: CNTB) is a clinical-stage biotechnology company advancing innovative therapeutics designed to transform the treatment landscape for inflammatory diseases driven by T-cell dysfunction. The company’s lead candidate, rademikibart, is a next-generation, highly differentiated monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα), with potential applications in asthma and chronic obstructive pulmonary disease (COPD)—markets collectively representing multi-billion-dollar commercial opportunities. Backed by robust clinical data from a global Phase 2 study demonstrating superior efficacy, rapid onset of action, and a favorable safety profile, Connect is strategically positioned to enter clinical trials targeting acute exacerbations in respiratory diseases, an ar...2025-04-1508 min
Cures & CapitalMatthias Krings on crafting winning biopharma strategies and smart decisionsIn this episode, our guest is Dr. Matthias Krings - a senior partner at Catenion, a biopharma strategy consulting firm.Matthias is a seasoned veteran in biopharma strategy.In this conversation, he shares his playbook for achieving success as a biopharma company.As critical pillars for biopharma success, we dive into strategy processes, decision-making, and effective R&D risk management.If you want to connect with us - we would love to hear from you:LinkedIn: https://www.linkedin.com/company/cures-capital-podcastYou can also watch the...2025-04-0749 min
AGORACOM Small Cap CEO InterviewsCanadian Small Cap Quantum BioPharma on The Verge of Multiple Sclerosis BreakthroughKEY MILESTONES AND WHAT’S NEXTSuccessful Phase 1 Trial: Lucid-MS has shown excellent safety with no serious side effects, paving the way for a groundbreaking treatment for MS.Next Major Step: The Phase 2 trial is set for early 2026, with 60 participants.FDA Submission on the Horizon: Plans to submit application to the FDA by late 2025, taking a huge step toward regulatory approval.Massive Market Opportunity: With 2.9 million people worldwide affected by Multiple Sclerosis and the market projected to surpass $30 billion by 2030, Lucid-MS could potentially capture a significant share of this rapidly expanding sp...2025-03-2520 min
AI News TrackerThe AI Transformation Accelerating Healthcare, Biopharma, and WellnessThe current state of the AI industry is marked by significant advancements and shifts in various sectors. Recent reports highlight AI's growing impact across healthcare, biopharma, and wellness, with AI adoption accelerating to enhance efficiency, improve patient outcomes, and drive financial ROI[1].In the healthcare sector, AI is being used to automate administrative workflows, reducing costs by 25-30% and freeing up resources for patient care. Predictive AI models are improving patient activation, cutting costs by 30% while increasing health plan revenues by 7%. Personalized digital interventions are lowering hospital stays by 25% and reducing nursing facility discharges by 91%[1].The...2025-02-0603 min
Mission Matters Innovation with Adam TorresNasdaq-listed Quantum BioPharma R&D Focused Business, Developing Solutions and TreatmentsQuantum BioPharma is developing a portfolio of products including Quantum's Lucid-MS drug development and their drink, unbuzzd. In this episode, Adam Torres and Jason Sawyer, Head of Finance & M&A at Quantum BioPharma, explore Quantum BioPharma.Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule.Apply to be a guest on our podcast:https://missionmatters.lpages.co/podcastguest/Visit our website:https://missionmatters.com/2025-01-3018 min
Mission Matters Business Podcast with Adam TorresNasdaq-listed Quantum BioPharma R&D Focused Business, Developing Solutions and TreatmentsQuantum BioPharma is developing a portfolio of products including Quantum's Lucid-MS drug development and their drink, unbuzzd. In this episode, Adam Torres and Jason Sawyer, Head of Finance & M&A at Quantum BioPharma, explore Quantum BioPharma.Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule.Apply to be a guest on our podcast:https://missionmatters.lpages.co/podcastguest/Visit our website:https://missionmatters.com/2025-01-3018 min
AGORACOM Small Cap CEO InterviewsQuantum BioPharma Sues CIBC, RBC & Others For $700 Million Alleging Spoofing/Short Selling Stock ManipulationQuantum BioPharma (Formerly FSD Pharma) has filed a groundbreaking $700 million lawsuit against major Canadian banks, CIBC and RBC, alleging a scheme of stock price manipulation known as "spoofing." CEO and Co-Chairman Zeeshan Saeed explains that this isn’t just a shot in the dark—industry experts estimate that damages could exceed $1 billion for $QNTM.
The company’s legal team, confident in the strength of the case, has agreed to take it on a contingency basis, signaling their belief that this could be a watershed moment for both Quantum BioPharma and the entire small cap sector.
“Our goal...2024-12-0236 min
Visionary Voices PodcastScaling Biopharma: A $600bn Industry ft Oscar GonzalezSummaryIn this conversation, Oscar Gonzalez shares his journey as a process consultant in the biopharma and biotech industries. He discusses the importance of optimizing internal operations, understanding clinical processes, and setting clear expectations with clients. Oscar emphasizes the need for effective communication and strategy in managing projects, as well as the challenges of scope creep and the significance of aligning goals within organizations. His insights provide a comprehensive view of the operational challenges faced in the biopharma sector and the strategies to overcome them. In this conversation, Oscar Gonzalez and Aqil discuss the importance...2024-11-2055 min
Evaluating BiopharmaEpisode: 23 - An Industry Veteran’s Insight on Data Governance and ProvenanceIn this episode of Evaluating Biopharma, host Ben Locwin and Scott Endicott, executive leader of Healthcare Solutions Integration, talk about data governance and data provenance—why they matter and how the industry can achieve them. With 30 years of experience, Endicott has a deep understanding of training AI and ML models, particularly when patient data is included, and offers advice on how to navigate the challenges of data governance and provenance in the near-term future. Links from this episode: Evaluating Biopharma Black Diamond Networks Evaluating Biopharma boiler: Evaluating Biopharma taps into th...2024-11-1216 min
Evaluating BiopharmaEpisode: 22 - Insider’s Advice for Starting, Growing, Exiting a BiotechIn this month’s episode of Evaluating Biopharma, host Ben Locwin and Chris Major, founder and partner of BioProcess360 Partners, discuss the best ways to start a company to address technology gaps, why it is beneficial to collaborate with competitors (instead of going against each other), and the challenges encountered when planning to de-risk portfolios in advance. Major also talks about how he approaches funding, the best practices and lessons he learned about time-to-exit strategies, and how his organization is paying it forward to the industry. Links from this episode: Evaluating Biopharma Black Diam...2024-10-0835 min
Investing InsightsHow GLP-1 Drugs Like Ozempic Are Boosting Biopharma StocksKaren Andersen, biotechnology strategist for Morningstar Research Services, discusses what GLP-1 drugs’ demand means for the biopharma industry’s five-year outlook. And whether the weight-loss drugs pose a threat to snack food stocks.Why GLP-1 Drugs Are in Demand Competition Between Novo Nordisk and Eli LillyHow Expanding the Conditions GLP-1 Drugs Treats Could Influence Insurance CoverageAre Weight Loss Drugs a Threat to Snack Food Stocks?Big Pharma’s Looming Patent CliffHow Medicare Negotiations Impact the Pharmaceutical IndustryWhat is a Biologic Drug?Up...2024-09-2714 min
Evaluating BiopharmaEpisode: 21 - How AI is Changing the Antibody R&D GameIn this month’s episode of Evaluating Biopharma, host Ben Locwin and Tony Arulanandam, SVP and head of R&D at Cytovia Therapeutics, discuss how AI is impacting the antibody R&D field, how companies are using AI to generate better sequences and improve efficacy, and methods on approaching regulators and tackling regulatory challenges. Arulanandam also talks about how he got started in biotech, getting therapies to underserved patient populations, and his thoughts on the promise of antibodies to treat cancer, autoimmune, and metabolic diseases. Evaluating Biopharma boiler: Evaluating Biopharma taps into the insight and experience of bio...2024-09-1031 min
BioSpaceA Tough Ending, New Beginnings and China-U.S. Biopharma RelationsGene editing startup Tome Biosciences is laying off nearly its entire workforce, as biopharma companies continue to face challenges in the current market. Meanwhile, Bayer, which cut 1,500 jobs in May, is parting with another 150 in Basel, Switzerland. On the other side of the spectrum, two new companies debuted last week. Novartis and Versant Ventures launched Borealis Biosciences to develop RNA medicines for kidney diseases, and BridgeBio spawned GondolaBio to focus on therapies for genetic and rare diseases. In Q2, biopharma VC funding reached its highest quarterly level since the same quarter in 2022, according to PitchBook.
Separately, U...2024-08-2815 min
The Agency AdvantageThe Realities of Corporate Life in Biopharma: What You Need to Know!Send us a textIn this episode of The Agency Advantage, I delve into what it's truly like to work in a corporate environment, specifically within a large biopharma company. Aimed at professionals looking to pivot from academia, smaller companies, or other sectors like medical practice or pharmacy, the discussion highlights the complexities of corporate life. Key topics include the politics, negotiation skills, and the sheer volume of people one interacts with. I break down various departments such as Access, Medical Affairs, Commercial, and Regulatory Affairs, emphasizing the importance of cross-functional collaboration and relationship building. Additionally, the...2024-08-2120 min
DarmglückSkeptisch, wer hinter Arktis BioPharma Schweiz und dem Team steckt? Heute erzähle ich dir unsere BackstoryWir bringen bald 20 Jahre Erfahrung im Bereich Darmgesundheit mit Diese Folge ist aus den Fragen einer Kundin entstanden. Sie wollte wissen, warum sie uns vertrauen sollte und warum sie gerade bei uns bestellen soll. Nachdem ich ihre Fragen beantwortet habe, dachte ich mir, es wäre schön, wenn es eine passende Podcastfolge gäbe. Eine Folge, die dir das Kennenlernen erleichtert, falls du skeptisch bist und uns noch nicht so gut kennst. Highlights dieser Folge · Was Roman und ich am Anfang unserer Zusammenarbeit angeboten haben · Warum wir viele auch int...2024-08-1334 min
RealPharma: Conversations with Pharma PathfindersAI Revolution: Transforming Biopharma with Andree BatesSummary
Dr. Andrée Bates, a pioneering force in the realm of artificial intelligence within the pharmaceutical industry, shares insights on the evolving role of AI in pharma, the future of healthcare innovation, and her advocacy for women in leadership.
She discusses the early days of AI in pharma, the challenges faced, and the evolution of AI terminology. Dr. Bates also explores the application of AI in commercial insights and analytics, market access, drug discovery, and clinical trials.
The conversation covers a wide range of topics related to the application of AI in t...2024-08-1251 min
Physician NonClinical Careers with John JuricaPriceless Advice From An Expert In The BioPharma IndustryLearn the business and management skills you need by enrolling in the University of Tennessee Physician Executive MBA program at nonclinicalphysicians.com/physicianmba. Get the FREE GUIDE to 10 Nonclinical Careers at nonclinicalphysicians.com/freeguide. Get a list of 70 nontraditional jobs at nonclinicalphysicians.com/70jobs. =============== Dr. Michelle Mudge-Riley is a physician career coach, consultant, entrepreneur, and leader. She’s also an expert in Global Strategy Development, Clinical Research, and Project Management in the Biopharma Industry. She is also schooled in physician career transition, partly because her career has continued to evolve...2024-08-0633 min
Evaluating BiopharmaEpisode: 20 - Optimal Talent Management in Biopharma with Mara Strandlund and Niamh AlixIn this month’s special episode of Evaluating Biopharma, host Ben Locwin interviews Mara Strandlund, chief people officer at National Resilience, and Niamh Alix, chief human resources officer at Prime Medicine, about the upcoming Talent in Biopharma Leadership workshop at the 2024 Bioprocessing Summit. Their conversation covers a wide variety of topics about talent management, including prioritizing talent retention, building agility into talent acquisition strategies, the importance of brand and culture, and more. They also share tips on what goes into creating a team of exceptional talent, as well as a sneak peek into the key themes of their opening ke...2024-07-1819 min
Evaluating BiopharmaEpisode: 19 - The Critical Role of Starting Materials & Processes in Advanced TherapiesIn this month’s episode of Evaluating Biopharma, host Ben Locwin and Joaquim Vives, head of production of advanced therapies at Banc de Sang i Teixits, discuss cell and gene therapies and what sets them apart from other therapeutics in terms of their processes. Vives also talks about the top characteristics of good starting materials and particular modes of handling logistics. He also delves into correlating a particular donor for a certain patient and shares where he sees the future of cell and gene therapy going. Evaluating Biopharma boiler: Evaluating Biopharma taps into the insight and experience of...2024-06-1117 min
The bluEPrint by Executive PlatformsThe Role CDMOs Play in the Future of Medicine — A Conversation with JR Humbert of INCOG BioPharma ServicesAt the 2024 edition of the Pharma Manufacturing World Summit held earlier this month in Boston, we spoke with JR Humbert, INCOG BioPharma Services’ VP Quality, about the crucial contributions CDMOs are making towards the future of medicine, both for large manufacturers and also for a whole range of new, small companies moving their Advanced Therapy Medicinal Products towards commercialization. What are the important issues pharmaceutical manufacturers need to be asking about and learning about as they choose how to partner with a third party to build up their capacity and capabilities? What does the working relationship need to look li...2024-05-3017 min
DarmglückQualitätssicherung und Produktion: ein Blick hinter die Kulissen von Arktis BioPharmaTransparenz in der Herstellung: So entstehen unsere Nahrungsergänzungsmittel In einer Zeit, in der das Vertrauen in Produkte oft auf dem Prüfstand steht, ist Qualität das A und O. In der aktuellen Folge des Darmglück Podcasts gewähre ich dir einen Blick hinter die Kulissen von Arktis BioPharma Deutschland. Du erfährst, wie Arktis BioPharma die hohen Qualitätsstandards in der Produktion von Nahrungsergänzungsmitteln sicherstellt. Übersicht Episoden-Themen Wie wir Arktis BioPharma überhaupt kennengelernt haben Die grosse Erfahrung der Gründer im Bereich Darmgesundheit Die Qualität der Rohsto...2024-05-2821 min
Diabetics Doing Things PodcastEpisode 281 - The Future of Closed Loop Diabetes Therapy - Xeris Biopharma and Beta BionicsIn this episode of Diabetics doing things, Rob interviews Paul Edick from
Xeris Biopharma and Sean Saint from Beta Bionics. They discuss the formal
partnership announcement between Xeris Biopharma and Beta Bionics, focusing
on the development of a bi-hormonal insulin pump for diabetes management.
The conversation touches on the challenges and benefits of the partnership,
the development process, and the potential impact on diabetes care.
Topics discussed:
1. Partnership between Xeris Biopharma and Beta Bionics
2. The unique challenges faced by a bihormonal pump compared to
traditional insulin pumps.
3. The formulation process of the pump and collaboration between Xeris
and Beta Bionics.
4...2024-05-2200 min
Evaluating BiopharmaEpisode: 18 - Bispecific Antibodies: What Are They? How Do They Work? An Expert's ThoughtsIn this episode of Evaluating Biopharma, host Ben Locwin speaks with Dr. Stefan Schmidt, CEO of evitria AG, about bispecific antibodies. Dr. Schmidt goes into detail about current trends (from a CRO’s perspective) regarding the discovery and development phases of bispecific antibodies, why they are being made, and potential manufacturing issues. He also discusses the future of bispecific antibodies and concerns over intellectual property immunity influencing consistency and production. Evaluating Biopharma boiler: Evaluating Biopharma taps into the insight and experience of biopharmaceutical leaders so today’s decision makers can leverage their knowledge, learn from their successes, and a...2024-05-1423 min
The Top LineA closer look at 2023's top biopharma deals and what lies aheadThis week on "The Top Line," we're diving into the details of the spree of big-money biopharma deals in 2023 and examining what that means for this year. Fierce Pharma Senior Writer Kevin Dunleavy sits down with Cody Powers, a consultant who advises companies on business development and franchise growth strategy, to discuss the reasons behind the numerous high-value deals in 2023, which companies are primed to make major moves this year, and whether the trend of acquiring ADCs and obesity treatments will continue. To learn more about the topics in this episode: The top 10 biopharma M...2024-05-0318 min
Physician NonClinical Careers with John JuricaThe Best Biopharma Positions For Motivated Practicing PhysiciansLearn the business and management skills you need by enrolling in the University of Tennessee Physician Executive MBA program at nonclinicalphysicians.com/physicianmba. Get the FREE GUIDE to 10 Nonclinical Careers at nonclinicalphysicians.com/freeguide. Get a list of 70 nontraditional jobs at nonclinicalphysicians.com/70jobs. =============== Dr. Nerissa Kreher is a pediatric endocrinologist and the Chief Medical Officer at a biotech company. She received her medical degree from East Carolina University. She then pursued her pediatric residency and pediatric endocrinology fellowship at Indiana University School of Medicine. She transitioned into the biopha...2024-04-2332 min
BiotalkBiotalk Episode 15: 2024 Q1 Report: Global Trends in Biopharma TransactionsDuring this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2024 Q1 Report: Global Trends in Biopharma Transactions Report. Each quarter, Locust Walk’s deal team compiles key statistics and trends showcasing the current state of global private and public capital markets, strategic partnerships, and M&A in the biopharma sector.
In this episode, Geoff provides valuable insights into our report, focusing on critical areas such as:
Biotech capital markets: Highlighting XBI’s recovery, strong market indicators, and increased PIPE activity since Q2 2023.
Private biotech markets: Saw the second-best deal quarter since 2021, yet activity remains flat com...2024-04-1611 min
RealPharma: Conversations with Pharma PathfindersVenture Capital & Biopharma: Jim Trenkle on Pioneering Health InnovationDive into the high-stakes world of Venture Capital in biopharma with Jim Trenkle! Have you ever wondered what it takes to turn groundbreaking scientific discoveries into life-saving treatments? What role do venture capitalists play in this thrilling journey from the lab to the clinic? This episode peels back the curtain on the biopharma venture capital scene, revealing the risks, rewards, and radical innovations driving the future of healthcare. Join hosts Dr. Na-Ri Oh and Ian Wendt as they explore with Jim the secrets of successful biopharma investments, the challenges of navigating the complex landscape of medical research funding, and...2024-04-0853 min
Evaluating BiopharmaEpisode: 17 - Essential Program Management Considerations for Biopharma With Jamie MartinIn this episode of Evaluating Biopharma, host Ben Locwin and Jamie Martin, PMP, senior consultant at Black Diamond Networks, discuss the tips and tricks of successful program management. Martin shares his mental checklist of must-haves to ensure a successful start, techniques on what to do when things fall off-track, and the keys to continuous success as the program is running. He also provides advice for listeners who may have newer programs or are new to program management, as well as the “best-in-class" tidbits they can immediately use. Links from this episode: Evaluating Biopharma Blac...2024-03-1222 min
Evaluating BiopharmaEpisode: 16 - Brian Tham on Project Management and Continuous Improvement in BiopharmaIn this episode of Evaluating Biopharma, host Ben Locwin speaks with Brian Tham, principal consultant at Peregrine Bio, LLC, on how various projects are run in the pharmaceutical industry, how to improve the outcome and processes of projects, and how to continue improving processes and operational excellence. They also delve into the history of how the car manufacturing industry influenced the quality management models and standards of the biotech and pharmaceutical industries. Finally, Tham shares his thoughts on the key differences between biotech and pharmaceuticals and other manufacturing industries, what this means for how development programs are managed, and...2024-03-1221 min
Scalecast#7 MEDEA Biopharma: Giorgi, spricht über die Revolution gegen Antibiotika-Resistenz mit Bakteriophagen. Im Fokus: Resilienz, Rückschläge und die inspirierende Philosophie von Arnold SchwarzeneggerIn diesem Gespräch geht es um MEDEA Biopharma, ein Biotech-Unternehmen, das nachhaltige antibakterielle Stoffe auf Basis von Bakteriophagen entwickelt. Bakteriophagen sind natürliche Mikroorganismen, die spezifisch Bakterien bekämpfen können. Das Unternehmen arbeitet an verschiedenen Anwendungen in der Landwirtschaft und im Pharmabereich, um das Problem der Antibiotika-Resistenz zu lösen. Giorgi, einer der Gründer von MEDEA Biopharma, erzählt von seiner Motivation und wie er auf das Thema aufmerksam wurde. Das Team von MEDEA Biopharma arbeitet daran, die Prozesse zu etablieren und langfristig eine Produktionsanlage aufzubauen. Giorgi betont die Bedeutung von Resilienz und Rationalität als Gründer...2024-02-2541 min
Evaluating BiopharmaEpisode: 15 - Facing CMC Challenges in CDMO-Sponsor Relationships for Rare Disease Platforms with Nesredin MussaIn this month’s episode of Evaluating Biopharma, host Ben Locwin speaks with Nesredin Mussa, PhD, president of Dynamica Biologics, about navigating the challenges of securing successful CDMO-sponsor relationships for a rare disease manufacturing and testing paradigm, the key contributing factors that may pose within the partnership between the sponsor and CDMO, and how small companies can manage with the enhanced regulatory demands due to the nascent nature of these particular therapeutic platforms. Mussa also provides advice on how to reframe one’s thinking when facing challenges, as well as techniques on keeping grounded when the going gets tough. 2024-02-1319 min
PharmaSource PodcastHow Gerresheimer are Transforming Biopharma Packaging and Delivery With Personalised and Sustainable Solutions“Small to midsize biotechs are the future of the biopharma industry” says Stefan Verhayden, Global Vice President of GX biological solutions and syringes at Gerresheimer. Stefan leads the company’s packaging and drug delivery services in the fast growing biopharma segment.
“They are the ones develop molecules that then afterwards, either go commercial to themselves or are being picked up by the bigger biopharma companies that then will bring them to a commercial phase.”
In the latest episode of the PharmaSource podcast, he explains some of the challenges biopharma customers...2024-02-0912 min
Insight Exchange by L.E.K. ConsultingLooking Ahead in Biopharma: 2024Today we venture into the crucial landscape of biopharma, anticipating the trends and challenges that will shape the industry in 2024. This episode aims to provide insights into the potential changes and advancements in the biopharmaceutical industry. It delves into various topics, including the use of artificial intelligence (AI) in drug discovery and different functional areas alongside challenges and strategies for enhancing commercial models with digital technologies. It also covers the impact of U.S. legislation on pharmacy operations, with a particular focus on maximum fair prices for prescription drugs and potentially greater transparency of the pharmacy benefit m...2024-01-2432 min
BioBreakthroughs#24 - J.D. Mowery, CEO of KBI BiopharmaJoin us on the latest episode! Our Guest: J.D. Mowery, CEO of KBI BiopharmaWhat you'll get out of this episode:Mowery's progression from the chemical industry to biopharma leadership.Exploration of Mowery's experiences in the industry.KBI BioPharma: Insights into the company's impact and role in the biopharmaceutical industry.Discussion on KBI BioPharma's international facilities and outreach.Mowery shares his strategic vision for KBI BioPharma and the evolving CDMO industry.A focus on the importance of customer relationships and collaborative approaches in biopharma.Mowery's thoughts on the future of biopharma and leadership.To...2023-11-1515 min
Evaluating BiopharmaEpisode: 14 - Strategies and Approaches for Process Intensification With Dr. Stefan Schmidtrocess intensification can be an overwhelming experience. In this episode of Evaluating Biopharma, host Ben Locwin speaks with Dr. Stefan Schmidt, CEO of evitria AG, about strategies and approaches that can help you understand and figure out how to navigate process intensification. Schmidt discusses ways to produce consistent results while using different equipment and technologies, how to find a balance between volume and capacity, and his experiences of putting proper support infrastructure as you go along the process. He also breaks down life cycle strategies and talks about downtime and its impact on the costs of the intensification strategy. 2023-11-1416 minPharmaSource PodcastAvantor: Flexible Fluid-Handling Biologics Solutions - interview with David Coorey, SVP Biopharma Business Development & Commercial OperationsAvantor is a Fortune 500 company with a wide range of mission-critical products and services for the biopharma industry.
David Coorey, SVP Biopharma Business Development & Commercial Operations at Avantor spoke to the PharmaSource podcast to explain more about the services they offer.
David explains how Avantor supports biopharma companies through R&D scientific discovery, to scale up and full commercial GMP manufacturing materials including custom use excipients and single use consumables.
“Avantor’s has evolved a unique ‘systems approach’ to designing full Fluid handling solutions for customers” says David. “We work with customers to design and o...2023-11-0307 min
DarmglückArktis BioPharma: Warum du dich ohne Bedenken für uns und unsere Produkte entscheiden kannstEs gibt mittlerweile viele Anbieter von Darmgesundheitsprodukten, probiotischen und präbiotischen Produkten. Was zeichnet uns - Arktis BioPharma Schweiz - aus? Punkte aus dieser Folge: 👉 Wir sind in der Schweiz tätig 👉 Unterschiede zwischen Arktis Biopharma Schweiz und Arktis BioPharma Deutschland und die verschiedene Regeln und Dosierungen bei bestimmten Produkten 👉 Langjährige Erfahrung im Bereich Darmgesundheit 👉 Qualität und Transparenz ist unsere oberste Priorität 👉 Reine Produkte ohne versteckte Inhaltsstoffe 👉 Von uns selbst getestet Produkte 👉 Roman und ich sind die Gründer und Inhaber von Arktis BioPharma Schwei...2023-10-3117 min
Evaluating BiopharmaEpisode: 13 - Identifying Impurities In Gene Therapy With Santoshkumar KhatwaniIn this episode of Evaluating Biopharma, host Ben Locwin speaks with Santoshkumar Khatwani, Director – Analytical Development, Late-Stage CMC Analytical Team Lead at Sangamo Therapeutics, about impurities in gene therapy processes and the ways to identify them. Khatwani discusses how to determine if these impurities are from the product, the process, or the host cell. He also talks about using multiple different analytical methods to help understand how good your process is or isn’t, what to look out for when prioritizing by phase, and how to choose the best approach to measure process attributes. Finally, he shares his thoughts on l...2023-10-2419 min
OUTCOMES - The Healthcare and Biopharma Marketing PodcastNavigating Nuances: A Holistic View of Digital Advertising in Healthcare and Biopharma🎙️ Welcome to another episode of OUTCOMES, your go-to podcast for healthcare and biopharma marketing insights.In this episode, we're thrilled to have Kristin Carlson and Michelle Deleppo, leading digital media strategists at emagineHealth. Together, they unpack the evolving landscape of digital marketing strategies tailored specifically for the healthcare and biopharma industries.🔍 What's Inside:1️⃣ Targeting Features in LinkedIn: Discover how new AI and other functionalities are revolutionizing targeting capabilities for marketers.2️⃣ Clinical Trial Recruitment: Learn about the unique challenges in the U.S. market and how to navigate through them.3️⃣ Regulatory Maze: Gai...2023-10-1732 minThe bluEPrint by Executive PlatformsRyan Crisman of Umoja Biopharma — Building Manufacturing In-House at an Early StageIn anticipation of the next edition of our long-running and successful Biomanufacturing World Summit series, we spoke with Ryan Crisman, the co-founder and Chief Technical Officer of Umoja Biopharma about the industry's current and future capacity challenges, and why Umoja chose to build its manufacturing in-house at an early stage, with some specific examples and references to Umoja’s new Colorado Laboratory & Innovative Manufacturing Building, which they call, ‘The CLIMB.’ We also discussed the issues of Talent and Leadership in a rapidly growing sector, and what organizations need to be doing individually and as a community to forge...2023-10-0228 min
Evaluating BiopharmaEpisode: 12 - The Risks and Rewards of Speed-to-IND Strategies With Susan JonesWhat are some strategies that companies can use to get to IND filing quickly? In this brand new conversation, Evaluating Biopharma podcast host Ben Locwin discusses the risks and rewards of speed-to-IND strategies with Susan Jones, Chief Technology Officer at Tourmaline Bio. Susan delves into her 30 years of experience in the biotech industry, how quality by design impacts IND filing, and the pitfalls of using platform approaches to accelerate early development. Finally, she shares some case studies where accelerated timelines led to unexpected outcomes, as well as advice on knowing your situation and risks, and spending time understanding your...2023-09-1119 min
BioTalk with Rich BendisHow the BioHealth Capital Region Became a Top 3 BioPharma Cluster: Insights from Alex Philippidis, Senior Business Editor at Genetic Engineering & Biotechnology NewsHow does a BioPharma Cluster ascend the ranks to secure a Top 3 position? What are the key factors propelling the BioHealth Capital Region to achieve its ambitious goal of ranking 3rd by 2023? Join us in this episode of BioTalk, where our host Rich Bendis speaks with Alex Philippidis, Senior Business Editor at Genetic Engineering & Biotechnology News. In this installment, Alex unveils the intricacies behind his latest Top 10 U.S. Biopharma Clusters, highlighting the impressive rise of the BioHealth Capital Region to its 3rd position. Learn about the origins of these rankings, the trends that have been identified for 2023...2023-08-1341 min
Evaluating BiopharmaEpisode: 11 - Cell Therapy Strategies: Preparing for Commercial Manufacturing of an Autologous Cell TherapyIn this episode of Evaluating Biopharma, host Ben Locwin, Vice President of Project Solutions at Black Diamond Networks, speaks with Jonathan Tsang, Senior Director, Manufacturing Sciences & Technology at Kite Pharma, who shares his experiences and provides advice on how autologous cell therapy companies can better prepare for commercial manufacturing, including: addressing the challenge of variability of patient cell behavior, process development characterization using healthy donor vs. patient cells, volume and logistical complexity of personalized therapy, and planning and implementing fast and efficient business systems to support scale-out. He also discusses critical quality attributes he looks for during process development...2023-08-1121 min
hagwinleowa[PDF] Free Download Do Quality Differently The Playbook for Creating More Success in Biopharma (or any) Manufacturing ((Read_[PDF]))Download Do Quality Differently: The Playbook for Creating More Success in Biopharma (or any) Manufacturing Full Edition,Full Version,Full Book by CLIFFORD BERRYReading Now at : https://happyreadingebook.club/?book=ORDOWNLOAD EBOOK NOW![PDF] Download [PDF] Free Download Do Quality Differently: The Playbook for Creating More Success in Biopharma (or any) Manufacturing ((Read_[PDF])) Ebook | READ ONLINE Download [PDF] Free Download Do Quality Differently: The Playbook for Creating More Success in Biopharma (or any) Manufacturing ((Read_[PDF])) read ebook online PDF EPUB KINDLE Download...2023-07-3100 min
Evaluating BiopharmaEpisode: 10 - Gene Therapy Analytics: How to Make the Right CMC Investments for Your BusinessIn this episode of Evaluating Biopharma, Mike Kelly, Senior Vice President at Atsena Therapeutics, shares his experiences and provides his advice on how your company can make proper CMC investments to reduce risk and maximize ROI, including: the make or buy decision, ensuring CMC investment to provide regulators what they need, scalability considerations, identifying technologies and assays to support your strategy, controlling COGS, and building a commercially feasible program profile. He also discusses factors that smaller businesses need to consider when choosing who to work with, such as fully understanding your needs and the compatibility between the sponsor and...2023-07-1122 min
Evaluating BiopharmaEpisode: 9 - Gene Therapy Analytics: Identifying and Overcoming CMC Challenges in Gene TherapyIn this episode of Evaluating Biopharma, Ben Locwin, Vice President of Project Solutions at Black Diamond Networks, speaks with Susan D'Costa, Chief Technology Officer at Alcyone Therapeutics, who shares her experiences and provides advice on how your company can identify and overcome CMC challenges in gene therapy, including: understanding and monitoring DNA constructs, identifying starting material challenges, prioritizing potency assays, and the impact of viral vector delivery and development of capsid tropism. D'Costa also talks about her hopes for the future of gene therapies and building better CMCs, processes, and characterization tools that will provide more accessible treatment for...2023-06-1324 min
Answers from the LabBioPharma Diagnostics: Bill Morice, M.D., Ph.D.Research and discoveries in the biopharmaceutical industry drive health care innovation and lead to new therapies for patients. When laboratories collaborate with biopharma, diagnostic, and biotech companies, it creates an integrated diagnostic ecosystem that can improve global health.In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to talk about the role of the biopharma industry and how Mayo Clinic BioPharma Diagnostics is fostering a di...2023-06-0815 min
Evaluating BiopharmaEpisode: 8 - The Financial Impact of a Continuous Bioprocessing StrategyJoseph Shultz, VP and technical head of biologics and vaccines at Resilience, and John Bonham-Carter, board member and VP of business development and product management at Erbi Biosystems, discuss the financial considerations biopharma companies face when implementing a continuous strategy. Shultz talks about the mindset of the senior leadership at Amgen—and then Novartis—that lead to the eventual adoption of a new bioprocessing system and how their strategies benefit multiple teams within a single organization. He also discusses the importance of setting key milestones to track successes and failures, the business parameters best suited for continuous bioprocessing, and the...2023-04-1120 minInsight Exchange by L.E.K. ConsultingFive Essential Factors for a Successful Biopharma Product LaunchRapid changes in the biopharma industry are making it increasingly difficult to launch new products successfully. Especially challenging are novel treatment modalities such as gene and cell therapy, the increased use of biomarkers, and expanded requirements to demonstrate economic value. In addition, biopharmas must navigate the declining access to physicians, digitalization, intense competition and the need to launch globally to maximize revenues. Faced with such challenges, biopharma companies must optimize their product launch planning and execution process to ensure successful launches of strong products, as covered in our previous piece, Key Indicators of a Successful Bi...2023-03-2224 min
Evaluating BiopharmaEpisode: 7 - Implementing an Efficient Allogeneic Cell Therapy Manufacturing StrategyMarty Giedlin, vice president and head of technology operations at Senti Bio, speaks with moderator Ben Locwin, vice president of project solutions at Black Diamond Networks, to share his experiences and provide advice on how allogeneic cell therapy companies can implement better manufacturing strategies. He discusses understanding and managing manufacturing expectations, letting biology drive strategic operations, and why data must drive chemistry, manufacturing, and controls. Giedlin also outlines how to best characterize starting materials, why a one-size-fits-all approach to process manufacturing is unrealistic, his predictions for the industry over the next five years, and his work developing NK-CAR treatments...2023-03-1427 min
Evaluating BiopharmaEpisode: 06 - Process Intensification: PAT, AI, ML to Support Intensified BioprocessingArthi Narayanan, innovation team leader of pharma technical operations at Genentech, and John Bonham-Carter, board member and VP of business development and product management at Erbi Biosystems, discuss how process analytical technology, artificial intelligence, and machine learning support intensified bioprocessing and improve inefficiencies. Narayanan talks about the expected outcomes predictive modeling will likely produce in the coming years, why data is the “power” of bioprocessing, and how to leverage predictive modeling to accelerate tech transfer. She also discusses the importance of accepting and trusting new technologies, the mindset surrounding data and employee acquisition that often leads to success, and how...2023-02-1419 min
Dissecting Popular IT Nerds184. What Makes Biopharma IT So Unique with Matthew DawsonMatthew Dawson Matthew Dawson is the Senior Director of IT at a biopharma company in the Dallas area. The biopharma space is uniquely different from his past experiences, especially because there is a lot of compliance. They have much more to deal with in terms of government processes and regulations. What Makes Biopharma IT So...2023-02-071h 13Dissecting Popular IT Nerds184. What Makes Biopharma IT So Unique with Matthew DawsonMatthew Dawson Matthew Dawson is the Senior Director of IT at a biopharma company in the Dallas area. The biopharma space is uniquely different from his past experiences, especially because there is a lot of compliance. They have much more to deal with in terms of government processes and regulations. What Makes Biopharma IT So...2023-02-071h 13
Dissecting Popular IT Nerds184. What Makes Biopharma IT So Unique with Matthew DawsonMatthew Dawson
Matthew Dawson is the Senior Director of IT at a biopharma company in the Dallas area. The biopharma space is uniquely different from his past experiences, especially because there is a lot of compliance. They have much more to deal with in terms of government processes and regulations.
What Makes Biopharma IT So Unique with Matthew Dawson
Matthew is a seasoned IT leader with a track record of successfully building teams that deliver solutions to enable the business. Even after decades working in this field, he still finds IT work interesting—es...2023-02-071h 13
Evaluating BiopharmaEpisode: 05 - Navigating Scale-Up Challenges in Protein ProductionParrish Galliher, an independent bioprocess consultant, speaks with moderator Ben Locwin, vice president of project solutions at Black Diamond Networks, about the context-dependent issues that arise when scaling-up protein production. Gallaher uses a case study involving scaling challenges in E. coli bioprocesses that produced a product at 50% potency. He also talks about the three main focus points every company should prioritize when assessing process development limitations, how to design scale-down studies to pinpoint causal factors, and how to use high-throughput screening for media optimization. Finally, he advises hiring first-rate process development experts to mitigate scaling issues from the start. 2023-01-1020 min
Gründer und Zünder: Der Startup Podcast#188 Replay: So funktionieren Pharma-Startups. 60 Millionen in 10 Jahren. Mit Lorenzo Corsini, PhagoMed BiopharmaReplay einer der beliebtesten Episoden aus 2020/21. Diese Episode wurde das erste Mal am 25.05.2020 als Episode #082 ausgestrahlt. Diese Woche zu Gast im Gründer & Zünder Podcast ist Lorenzo Corsini, Co-Founder von PhagoMed Biopharma. PhagoMed Biopharma sitzt in Wien und besteht zum Großteil aus Forschern. Lorenzo hat das Startup zusammen mit seinem Co-Founder und Co-Geschäftsführer Alexander Belcredi gegründet, beide haben BCG-Vergangenheit und sind waschechte Business-People. In dieser Episode spricht Lorenzo darüber: Wie Biopharma-Startups funktionieren. Warum es 10-12 Jahre und über 60 Millionen Euro braucht bis das Endprodukt am Markt ist und w...2022-12-2851 min
Drug SolutionsOutsourcing vs. Insourcing in Biopharma: Determining the Best Strategy: Part 2How can organizations determine when to outsource vs. insource? What factors can (or should) be considered? The right outsourcing strategy has the potential to limit unnecessary costs, maintain output and turnaround times, and enable continued flexibility. In part two of this outsourcing series, Meg Rivers and Jeff Henderson, key account manager of Vetter, discuss: 1) what the biopharma industry currently tends to outsource, 2) outsourcing strategies the biopharma industry should be utilizing, 3) internal tasks the biopharma industry should consider outsourcing more in development and manufacturing, 4) what the biopharma industry should reconsider outsourcing and instead perform in-house, and 5) what organizations are choosing not...2022-12-2025 min
Evaluating BiopharmaEpisode 4: Anticipating Disruptions: Identifying and Planning for ShortagesIn the biopharma space, nearly every moving part is contingent upon a functioning supply chain. In this month’s episode, moderator Ben Locwin, vice president of project solutions at Black Diamond Networks, speaks with Rich Musa, director and head of supply chain at Cipla Therapeutics, about anticipating supply chain disruptions and planning for shortages. Musa talks about maintaining materials inventory, structuring robust supplier contracts, securing backup suppliers, and investing in a third-party supply chain analysis. He also outlines the proper way to forecast materials, manage risk versus loss, and prepare suppliers to meet demand requirements in a dynamic environment. 2022-12-2019 min
Evaluating BiopharmaEpisode: 3 - Cell and Gene Therapy: Managing the ‘Build or Buy’ DecisionDave Backer, founder of DB Biologics and former chief commercial officer at Oxford Biomedica, speaks with moderator Ben Locwin, vice president of project solutions at Black Diamond Networks, about the complex business and technological decisions companies face when navigating supply chain issues in the cell and gene therapy (CGT) market. Today’s companies must decide whether to build new facilities and produce their own supplies, continue buying from CDMOs despite excessive lead times, or choose a hybrid model. In this episode, Backer outlines the critical factors every CGT company should consider before venturing into manufacturing. He talks abo...2022-11-0822 min
Project Management ParadiseEpisode 147: “Keys to Effective Project Prioritization in Biopharma” with Joe StalderJoe Stalder has over 10 years of experience managing drug development projects in a variety of company sizes and cultures, including Pfizer, Roche, and AstraZeneca. Joe is a regular speaker at biopharma project and portfolio management conferences and he’s the author of an upcoming book on managing drug development projects. In this episode, Joe Stalder is going to discuss: “Keys to Effective Project Prioritization in Biopharma”. Learn the keys to effective “project prioritization in biopharma” by accessing a complimentary guidebook by Joe Stalder at https://corasystems.com/prioritizationguide Tune in to a bonus we...2022-10-2426 min
Evaluating BiopharmaEpisode: 2 - Operational Efficiencies: Lower Operational Costs by Reducing Clinical GMP SamplingIn this episode, Josefine Persson, Genentech associate director, and Ben Locwin, Black Diamond Networks vice president of project solutions, discuss how the cost of oversampling from clinical GMP runs versus development sources equates to high expenses and lost opportunities in moving a new project into GMP manufacturing. Persson also talks about the role judicious sampling plays in testing and verifying process operations and how she worked with various Genentech departments to reduce product sampling volumes by more than 50 percent. She goes on to discuss the importance of changing the company mindset to encourage behaviors based on department n...2022-10-1125 min
Investing, Markets & MoneyM&A activity in Biopharma with Datasite | Ep.60In the first episode of season 3 we discuss the Biopharma industry with Merlin Piscitelli, Chief Revenue Officer of Datasite, SaaS solutions provider for M&A. How will biopharma weather the current economic storm, how is M&A looking and what are the areas being most intensely researched.
Get our free daily newsletter on market movers at www.thearmchairtrader.com
If there are companies you would like the Armchair Trader to feature in future episodes reach us on www.thearmchairtrader.com
0.37 A summary of recent activity
2.10 Do you anticipate more major acquisitions?
3.27 Are recent valuations unrealistically high?
6.55 Is there an innovation...2022-09-1526 min
Evaluating BiopharmaEpisode 000: Introducing the Evaluating Biopharma PodcastEvaluating Biopharma taps into the insight and experience of biopharmaceutical leaders so today’s decision makers can leverage their knowledge, learn from their successes, and avoid repeating similar mistakes. This series offers a new guest and moderator with each episode and aims to equip executives and science leaders with the necessary information to make better business and process decisions. The Evaluating Biopharma podcast is a reproduction of content originally presented at recent Evaluating Biopharma digital and educational networking events.Evaluating Biopharma boiler: Evaluating Biopharma taps into the insight and experience of biopharmaceutical leaders so today’s decision make...2022-09-1302 min
Evaluating BiopharmaEpisode 001: The Continuous Learning Curve: CPI’s Simon Hawdon on Process Conversion, Product Quality, and Platform SelectionIn the inaugural episode of Evaluating Biopharma podcast, CPI’s Simon Hawdon speaks with Moderator John Bonham-Carter about the benefits of converting from batch to continuous processing and the critical decisions involved in making a high-quality product. Hawdon talks about whether there is an optimal time for process conversion, key equipment features that facilitate automation, and why improved sensors are imperative for process development. Finally, Hawdon shares his predictions on when he thinks real-time release sensors will debut and why necessity will always drive industry growth. Links from this episode: Evaluating Biopharma Centre for...2022-09-1321 min
Definitively SpeakingEpisode 13 afterward: The biopharma glass is definitively more than half-fullJustin, Todd, and special guest Robert Groebel, VP of global life science strategy at Definitive Healthcare, expand on last week’s chat with Pam Randhawa from Empiriko and unpack the challenges, benefits, and opportunities of collaboration in the biopharma market. How can big pharma, small pharma, academia, and the government all work together? Robert and Todd have some big ideas. They look back at their careers to share professional insights and personal perspectives on the biopharma industry’s evolving playbook—and why they’re looking forward with a healthy dose of optimism. Justin asks Todd and Robe...2022-09-0829 min
Drug SolutionsOutsourcing vs. Insourcing in Biopharma: Determining the Best StrategyIn what instances should organizations outsource vs. insource? Determining the right outsourcing strategy is key to limit unnecessary costs, maintain output and turnaround times, and enable continued flexibility. Meg Rivers, senior editor for Pharmaceutical Technology, and John Koleng, VP of product development and manufacturing for TFF Pharmaceuticals, will discuss: 1) what the biopharma industry currently tends to outsource, 2) outsourcing strategies the biopharma industry should be utilizing, 3) internal tasks the biopharma industry should consider outsourcing more in development and manufacturing, 4) what the biopharma industry should reconsider outsourcing and instead perform in-house, and 5) what organizations are choosing not to outsource and why.
SPONSORS...2022-08-1638 min
Pharmaceutical ExecutiveNew Guidance For Biopharma Investor ESG CommunicationsMyrto Kontaxi, a partner in the Biopharma Sustainability Roundtable, and lead author on its updated Biopharma Investor ESG Communications Guidance; and Victoria Emerick, global head of sustainability strategy and operations at Bristol Myers Squibb, a Biopharma Sustainability Roundtable participant, and a key contributor to the Guidance development process, discuss the growing demand for better communication about ESG strategy and performance, and how the updated ESG Guidance can help both biopharma companies and investors respond.2022-05-2621 min
From Lab to Launch by QualioRebuilding Biopharma & Personalized Precision Medicine with Diego Rey Cofounder of Endpoint Health and YC GradWhat if you started a company like Roche (est. in 1896) from the ground up? How would you approach drug development differently given enabling technology available today? That's the question Diego Rey and the other founders of Endpoint Health asked. Diego Rey is a co-founder and Chief Scientific Office of Endpoint Health, which is flipping the traditional drug development model on its head with a precision-medicine approach. In the past, biopharma companies would start with a molecule and then see where it can be used. Endpoint thinks differently. They are using deep patient insight from the patient’s bio...2022-05-1818 min
Weaver: Beyond the NumbersThe Rebound and Current Financial State of the Biopharma and Med Tech IndustriesCOVID-19 rocked the world in most industries, but particularly for biopharma and pharmaceuticals, which were at the forefront. Tyler Ridley, Senior Manager of Valuation Services at Weaver, joined this episode of Weaver: Beyond The Numbers Podcast with Weaver hosts Howard Altshuler, Partner-In-Charge of Real Estate Services, and Rob Nowak, Tax Partner with Weaver, to discuss the rebound and current financial state of the biopharma and med tech industries.Since the pandemic, the spike in healthcare initial public offerings (IPOs) and performance solidified the IPO pathway and exit strategy for life science investors. “I think it’s a shif...2022-01-1307 min
Weaver: Beyond the NumbersThe Rebound and Current Financial State of the Biopharma and Med Tech IndustriesCOVID-19 rocked the world in most industries, but particularly for biopharma and pharmaceuticals, which were at the forefront. Tyler Ridley, Senior Manager of Valuation Services at Weaver, joined this episode of Weaver: Beyond The Numbers Podcast with Weaver hosts Howard Altshuler, Partner-In-Charge of Real Estate Services, and Rob Nowak, Tax Partner with Weaver, to discuss the rebound and current financial state of the biopharma and med tech industries.Since the pandemic, the spike in healthcare initial public offerings (IPOs) and performance solidified the IPO pathway and exit strategy for life science investors. “I think it’s a shif...2022-01-1307 min
Weaver: Beyond the NumbersEp 1053: The Rebound and Current Financial State of the Biopharma and Med Tech IndustriesCOVID-19 rocked the world in most industries, but particularly for biopharma and pharmaceuticals, which were at the forefront. Tyler Ridley, Senior Manager of Valuation Services at Weaver, joined this episode of Weaver: Beyond The Numbers Podcast with Weaver hosts Howard Altshuler, Partner-In-Charge of Real Estate Services, and Rob Nowak, Tax Partner with Weaver, to discuss the rebound and current financial state of the biopharma and med tech industries.Since the pandemic, the spike in healthcare initial public offerings (IPOs) and performance solidified the IPO pathway and exit strategy for life science investors. “I think it’s a shif...2021-12-2907 min
Discovery Matters46. The pulse of the industry - BioPlan and the Biopharma Resilience IndexFor this episode of Discovery Matters we are focusing on industry surveys and what they can tell us. This includes BioPlan and the Biopharma Resilience Index. Both huge reports providing insight into both the issues and opportunities facing the industry today. Firman Ghouze, Cytiva’s Marketing Director in APAC, explains how the Biopharma Resilience Index came about, the industry issues it uncovers and potential solutions. We are also joined by Eric Langer, from BioPlan Associates, to discuss the BioPlan findings and how they echo many of the same themes. Finally, it was a delight to talk to Dr. Richard Wang, th...2021-12-0918 min
Discovery Matters46. The pulse of the industry - BioPlan and the Biopharma Resilience IndexFor this episode of Discovery Matters we are focusing on industry surveys and what they can tell us. This includes BioPlan and the Biopharma Resilience Index. Both huge reports providing insight into both the issues and opportunities facing the industry today.
Firman Ghouze, Cytiva’s Marketing Director in APAC, explains how the Biopharma Resilience Index came about, the industry issues it uncovers and potential solutions. We are also joined by Eric Langer, from BioPlan Associates, to discuss the BioPlan findings and how they echo many of the same themes. Finally, it was a delight to talk to Dr...2021-12-0918 min
Translating AgingDISCO: A New Model for Entrepreneurship in Longevity Biotech (Dr. James Peyer — Cambrian Biopharma)Dr. James Peyer, PhD, is the Founder and CEO of Cambrian Biopharma, a Distributed xDevelopment Company developing therapeutics targeting the biological drivers of aging.Cambrian Biopharma brings together experts, scientists, and experienced company builders in a new model of entrepreneurship related to health span and aging. Dr. Peyer was previously the founder of Apollo Ventures, a successful venture capital firm focused on the longevity biotech space. He has spoken on the topic of longevity biotech and investing for Bloomberg, The Economist, TEDx, Longevity Leaders, ETH Zurich, and the Max Planck Institute on the Biology of Aging.2021-12-0145 min
Anything is Possible with Patrick TsangAnthony Cataldo: CEO of GT BioPharma | Anything is Possible with Patrick TsangPatrick Tsang interviews Anthony Cataldo, the CEO of GT Biopharma, a clinical-stage immuno-oncology company developing innovative therapies based on proprietary NK cell engager (TriKE®) technology. In this interview in Monaco, Anthony shares his career path, including Iovance Biotherapeutics, leading to his work in immuno-oncology with GT Biopharma, and lessons learned becoming CEO. He speaks about the importance of data and clinical trials for GT Biopharma to target cancers such as acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia, and multiple solid tumors. In addition, he has extensive experience in the biotechnology sector.
More about Anthony Cataldo:
2021-09-1416 min
Biopharma EHSBiopharma EHS Podcast Episode 28 - PDE reportsBioPharma EH&S Podcast Episode No. 28. Hello everybody and welcome back to another Episode of the BioPharma EH&S Podcast, my name is Dean Calhoun of Affygility Solutions and this is the podcast dedicated to discussing critical environmental, health and safety issues facing the biopharma industry, helping you take your environmental, health and safety programs to the next level. Well, it’s Monday, June 14th, 2021 and I’m excited to be back today recording today. We have full show for today and a lot of great things to talk about, so let’s go ahead and ge...2021-06-1418 min